Silo Pharma And Resyca Partner For Study Of Intranasal SPC-15 Delivery System For PTSD

Silo Pharma, Inc., a biopharmaceutical company developing innovative therapeutics and drug delivery technologies, announced a new service agreement with Resyca BV, a medical technology firm. The agreement supports a drug-device study focused on the microchip-enabled nasal spray delivery system for SPC-15, Silo’s lead investigational treatment aimed at preventing post-traumatic stress disorder (PTSD).

“This study is expected to provide the final necessary device data and documentation for SPC-15’s IND, which we plan to submit to the FDA this year. Our chosen device transports the molecules to the brain directly, bypassing the blood-brain barrier, to increase drug concentration. We believe this method can drive faster onset of therapeutic benefit with optimized safety for the treatment of PTSD patients,” said Eric Weisblum, CEO of Silo. 

The drug-device study will evaluate how Resyca’s nasal spray technology works with SPC-15’s specific formulation, optimizing intranasal delivery. SPC-15 is designed as a prophylactic therapy, targeting PTSD before symptoms fully manifest. In parallel, Silo is conducting two other key studies to advance SPC-15 toward clinical trials: an IND-enabling GLP-compliant toxicology and toxicokinetics study, and a 7-day safety/toxicology large animal study, which was requested by the FDA.